FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off 
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Thailand Inflation Remains Negative for 10th Straight Month in January 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal 
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record 
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Mizuho has unveiled its January US Top Picks, spotlighting Chewy, GE Vernova, Enliven Therapeutics, Quest Diagnostics, DuPont, and Salesforce. These companies align with Mizuho’s high-conviction investment ideas, driven by expected catalysts over the next year.
Chewy earned a spot for its strong EBITDA margin expansion, supported by automation, vet-focused initiatives, and app engagement. With a $42 price target, analysts see a 17% upside for the pet retailer.
GE Vernova stands out as a key player in power generation, providing turbines and grid equipment that supply 30% of global electricity. Mizuho forecasts significant growth in natural gas power contracts by 2025, driven by rising data center demand.
Enliven Therapeutics shows promise with ELVN-001, an investigational tyrosine kinase inhibitor (TKI) demonstrating early efficacy in chronic myeloid leukemia (CML). Analysts see potential for ELVN-001 to expand into first-line treatment, bolstering its market outlook.
Quest Diagnostics appeals for its stable cash flow and growth opportunities in diagnostics, underpinned by Medicare and commercial pricing strength. Mizuho highlights its acquisition pipeline and EPS growth forecast for 2025.
DuPont’s planned split into ElectronicsCo, WaterCo, and the new DuPont is seen as a value catalyst. Analysts cite the company’s leadership in specialty materials like Kevlar and Tyvek, alongside seasonal sales recovery and electronics growth.
Salesforce rounds out the list, with Data Cloud and Agentforce technology driving productivity and revenue growth. Upcoming updates, multi-cloud deals, and margin improvements position Salesforce for continued success in digital transformation.
These additions reflect Mizuho’s strategic outlook for 2024, showcasing diverse opportunities across industries.
